In pre-clinical models of classically inflamed solid tumors, intratumoral (i.t.)small molecule STING agonists can induce dramatic local tumor regression and systemic immunity against distant disease and this strategy has now entered early phase clinical trials. The gene discussed is STING1; the disease is neoplasm.